COMPANY:

Nucleai

"Nucleai...will showcase its expanded suite of solutions for antibody-drug conjugate (ADC) clinical trials at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, held this week from May 30-June 3 in Chicago, IL. Recent studies have demonstrated that AI-powered computational pathology and spatial biomarkers can predict ADC treatment response more accurately than standard pathological scores, enabling ADC developers to derisk their drug development programs by designing biomarker-informed clinical trials. Nucleai’s commercially available ADC suite of solutions unlocks unparalleled granularity for ADC developers, including high sensitivity for low levels of biomarker expression as well as detecting subcellular protein expression."

"First Abstract: Addressing Immunotherapy Resistance in NSCLC - In collaboration with Dr. Arutha Kulasinghe of The University of Queensland and Dr. David Rimm from Yale University, the first abstract profiles the metabolic states of tumor and immune cells in NSCLC patients treated with checkpoint inhibitors....Second Abstract: Integrating Spatial Biomarker Analysis in Melanoma - The second abstract, in collaboration with Dr. Paolo Ascertio and Lunaphore, a Bio-Techne brand, examines the spatial proteomic profile of melanoma patients undergoing immunotherapy as part of the SECOMBIT trial."

"Nucleai...announced a strategic collaboration with GoPath Diagnostics...This collaboration aims to offer AI-powered digital pathology solutions for clinical trials and diagnostics and foster innovative research by combining Nucleai’s expertise in spatial biology and AI with GoPath’s access to multi-modal real-world data, world-class lab services, and cutting-edge molecular capabilities."

"AI-driven spatial biology offers enhanced insights from cancer biopsies, catering to novel biomarker discoveries in translational research and accurate, automated analysis of traditional pathology slides for improved diagnostics and treatments. Advancements demonstrate integration of novel spatial biology methods with AI to empower investigators in advancing cancer research and enhance insights from traditional diagnostic pathology methods such as H&E staining."

"Nucleai...has secured a $14 million investment led by M Ventures, the corporate venture capital arm of Merck KGaA, Darmstadt, Germany, and supported by existing investors, bringing the total funding to $60 million. The investment enables Nucleai to further deploy its AI algorithms for the prospective enrollment of patients in clinical trials – a first in the field and a significant advancement in personalized solutions tailored to the distinct needs of patients."

"Nucleai...and Mayo Clinic BioPharma Diagnostics are pleased to announce a strategic collaboration to bring world-class digital pathology solutions, technologies, and services to support drug development and clinical practice."